• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.头孢吡肟精准剂量工具:基于非参数群体药代动力学的从标准剂量到精准剂量。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0204621. doi: 10.1128/AAC.02046-21. Epub 2021 Dec 13.
2
Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.群体药代动力学与危重症患者头孢吡肟的目标浓度达成及初始给药剂量指导
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00745-20.
3
Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.高剂量、延长输注时间的头孢吡肟在成人呼吸机相关性肺炎重症患者中的群体药代动力学。
Antimicrob Agents Chemother. 2009 Apr;53(4):1476-81. doi: 10.1128/AAC.01141-08. Epub 2009 Feb 2.
4
Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.头孢吡肟在中性粒细胞减少性发热患者中的群体药代动力学:与剂量依赖性敏感性和当代给药方案的关系。
Int J Antimicrob Agents. 2017 Sep;50(3):482-486. doi: 10.1016/j.ijantimicag.2017.04.008. Epub 2017 Jun 28.
5
Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).接受体外膜肺氧合(ASAP ECMO 研究)的危重症患者中头孢吡肟的群体药代动力学。
Int J Antimicrob Agents. 2021 Dec;58(6):106466. doi: 10.1016/j.ijantimicag.2021.106466. Epub 2021 Oct 21.
6
Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).接受体外膜肺氧合(ECMO)治疗的危重症患者中头孢吡肟的药代动力学和 MIC 以上暴露时间。
Int J Antimicrob Agents. 2022 Jul;60(1):106603. doi: 10.1016/j.ijantimicag.2022.106603. Epub 2022 May 14.
7
Pharmacokinetics of Cefepime in Children on Extracorporeal Membrane Oxygenation: External Model Validation, Model Improvement and Dose Optimization.头孢吡肟在体外膜肺氧合患儿中的药代动力学:外部模型验证、模型改进和剂量优化。
Pediatr Infect Dis J. 2022 Mar 1;41(3):217-223. doi: 10.1097/INF.0000000000003371.
8
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.重症监护病房中头孢吡肟给药方案的药代动力学-药效学原理
J Antimicrob Chemother. 2006 Nov;58(5):987-93. doi: 10.1093/jac/dkl349. Epub 2006 Aug 30.
9
Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.头孢吡肟在不同肾功能危重症儿童中的群体药动学和给药方案优化。
Clin Microbiol Infect. 2022 Oct;28(10):1389.e1-1389.e7. doi: 10.1016/j.cmi.2022.05.007. Epub 2022 May 20.
10
Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.连续肾脏替代治疗的危重症患者中头孢吡肟延长输注的药代动力学和药效学:一项前瞻性、开放标签研究。
Pharmacotherapy. 2019 Nov;39(11):1066-1076. doi: 10.1002/phar.2332. Epub 2019 Oct 22.

引用本文的文献

1
Cefepime Daily Exposure and the Associated Impact on the Change in Sequential Organ Failure Assessment Scores and Vasopressors Requirement in Critically Ill Patients Using Repeated-Measures Mixed-Effect Modeling.使用重复测量混合效应模型评估头孢吡肟每日暴露量及其对重症患者序贯器官衰竭评估评分变化和血管升压药需求的相关影响。
Crit Care Explor. 2023 Oct 27;5(11):e0993. doi: 10.1097/CCE.0000000000000993. eCollection 2023 Nov.
2
Impact of Beta-Lactam Target Attainment on Resistance Development in Patients with Gram-Negative Infections.β-内酰胺类药物靶点达成情况对革兰阴性菌感染患者耐药性发展的影响
Antibiotics (Basel). 2023 Dec 3;12(12):1696. doi: 10.3390/antibiotics12121696.
3
Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.群体药代动力学和目标达成分析,以确定危重症患者头孢吡肟的合理经验性给药策略。
J Antimicrob Chemother. 2023 Jun 1;78(6):1460-1470. doi: 10.1093/jac/dkad106.
4
Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia.利用机器学习定义 ICU 中获得性医院肺炎和呼吸机相关性肺炎患者β-内酰胺早期和累积目标达标对结局的影响。
Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0056322. doi: 10.1128/aac.00563-22. Epub 2022 Jun 14.

本文引用的文献

1
Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines.评估头孢吡肟的毒代动力学:全面研究头孢吡肟引起的神经毒性的药代动力学/药效学目标,并评价当前的给药指南。
Int J Antimicrob Agents. 2021 Dec;58(6):106443. doi: 10.1016/j.ijantimicag.2021.106443. Epub 2021 Sep 20.
2
Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis.囊性纤维化儿科患者中妥布霉素的群体药代动力学建模与给药模拟
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0073721. doi: 10.1128/AAC.00737-21. Epub 2021 Jul 19.
3
To Estimate or to Forecast? Lessons From a Comparative Analysis of Four Bayesian Fitting Methods Based on Nonparametric Models.估算还是预测?基于非参数模型的四种贝叶斯拟合方法的比较分析得出的结论。
Ther Drug Monit. 2021 Aug 1;43(4):461-471. doi: 10.1097/FTD.0000000000000879.
4
Using precision dosing to minimize cefepime-induced neurotoxicity: The challenge of targets.采用精准给药以将头孢吡肟所致神经毒性降至最低:靶点面临的挑战。
J Infect Chemother. 2021 Jun;27(6):929-930. doi: 10.1016/j.jiac.2021.02.020. Epub 2021 Mar 2.
5
Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).β-内酰胺类抗生素在危重症患者中未达到目标治疗效果的失败率及其相关危险因素:一项多中心前瞻性研究(EXPAT)。
Crit Care. 2020 Sep 15;24(1):558. doi: 10.1186/s13054-020-03272-z.
6
Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.群体药代动力学与危重症患者头孢吡肟的目标浓度达成及初始给药剂量指导
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00745-20.
7
Antimicrobial Use in US Hospitals: Comparison of Results From Emerging Infections Program Prevalence Surveys, 2015 and 2011.美国医院的抗菌药物使用情况:2015年与2011年新发感染项目患病率调查结果比较
Clin Infect Dis. 2021 May 18;72(10):1784-1792. doi: 10.1093/cid/ciaa373.
8
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.危重症成人患者的抗菌治疗药物监测:立场文件。
Intensive Care Med. 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1. Epub 2020 May 7.
9
Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime.开发人口和贝叶斯模型,用于接受头孢吡肟治疗的患者的应用。
Clin Pharmacokinet. 2020 Aug;59(8):1027-1036. doi: 10.1007/s40262-020-00873-3.
10
Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients.重症患者中阿米卡星的初始剂量:优化个体患者药代动力学/药效学目标达成的非参数方法。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.00993-19. Print 2019 Nov.

头孢吡肟精准剂量工具:基于非参数群体药代动力学的从标准剂量到精准剂量。

Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.

机构信息

Infectious Disease Pharmacokinetics Lab, Emerging Pathogens Institute, University of Floridagrid.15276.37, Gainesville, Florida, USA.

Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Floridagrid.15276.37, Gainesville, Florida, USA.

出版信息

Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0204621. doi: 10.1128/AAC.02046-21. Epub 2021 Dec 13.

DOI:10.1128/AAC.02046-21
PMID:34902271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8846452/
Abstract

Cefepime is the second most common cephalosporin used in U.S. hospitals. We aim to develop and validate a cefepime population pharmacokinetic (PK) model and integrate it into a precision dosing tool for implementation. Two data sets (680 patients) were used to build the cefepime PK model in Pmetrics, and three data sets (34 patients) were used for the validation. A separate application data set (115 patients) was used for the implementation and validation of a precision dosing tool. The model support points and covariates were used to generate the optimal initial dose (OID). Cefepime PK was described by a two-compartment model including weight and creatinine clearance (CrCl) as covariates. The median rate of elimination was 0.30 h (adults) and 0.96 h (children), the central volume of distribution was 13.85 L, and the rate of transfer from the central to the peripheral compartments was 1.22 h and from the peripheral to the central compartments was 1.38 h. After integration in BestDose, the observed versus predicted cefepime concentration fit using the application data set was excellent ( > 0.98), and the median difference between what was observed and what BestDose predicted on a second occasion was 4%. For the OID, cefepime at a 0.5- to 1-g 4-h infusion every 8 to 24 h (q8 to 24 h) with a CrCl of <70 mL/min was needed to achieve a target range of free trough:MIC 1 to 4 at a MIC of 8 mg/L, while continuous infusion was needed for higher CrCl and weight values. In conclusion, we developed and validated a cefepime model for clinical application. The model was integrated in a precision dosing tool for implementation, and the median concentration prediction bias was 4%. The OID algorithm was provided.

摘要

头孢吡肟是美国医院第二常用的头孢菌素。我们旨在开发和验证头孢吡肟群体药代动力学(PK)模型,并将其整合到精确给药工具中以实施。两个数据集(680 名患者)用于在 Pmetrics 中建立头孢吡肟 PK 模型,三个数据集(34 名患者)用于验证。另一个应用数据集(115 名患者)用于精确给药工具的实施和验证。模型支持点和协变量用于生成最佳初始剂量(OID)。头孢吡肟 PK 采用包括体重和肌酐清除率(CrCl)作为协变量的两室模型进行描述。消除的中位数速率为 0.30h(成人)和 0.96h(儿童),中心分布容积为 13.85L,从中枢向周围室的转移率为 1.22h,从周围向中央室的转移率为 1.38h。在 BestDose 中集成后,应用数据集的观察到的与预测的头孢吡肟浓度拟合非常好(>0.98),并且第二次观察到的与 BestDose 预测的中位数差异为 4%。对于 OID,在 CrCl<70mL/min 时,需要每 8 至 24 小时(q8 至 24 小时)给予 0.5 至 1 克 4 小时输注头孢吡肟,以实现游离谷值:MIC1 至 4 的目标范围在 MIC 为 8mg/L 时,而对于更高的 CrCl 和体重值,则需要连续输注。总之,我们开发并验证了用于临床应用的头孢吡肟模型。该模型已整合到精确给药工具中以实施,中值浓度预测偏差为 4%。提供了 OID 算法。